In the presence of heterozygous BRCA1 pathogenic variants (PV), but without associated clinical signs of FA, and in the absence of a familial history of breast or ovarian cancers, an assessment of the actual oncological risk in this patient is difficult. The gene discussed is BRCA1; the disease is ovarian cancer.